Antibody-Protein L Functionalized Microparticles for Detection of Surface Markers in Heterogeneous Colorectal Lesions

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text

The study developed antibody-protein L functionalized microparticles (APL-MPs) to detect multiple colorectal cancer surface biomarkers despite tumor heterogeneity and temporal changes, focusing on two targets: MUC1 and EPCAM. Using colon tumor tissue arrays and surveys of CRC cell lines in 2D cultures and 3D tumoroids, the authors identified MUC1 and EPCAM as a useful targeting pair and implemented them simultaneously on “universal” APL-MPs. In heterogeneous tumoroids expressing both antigens and in orthotopic animal models engineered to express both surface markers, APL-MPs detected MUC1- and EPCAM-positive cells in proportion to antigen expression and showed detection of CRC surface antigens on the luminal colon surface in vivo, with improved sensitivity from concurrent multi-antigen targeting. The paper’s limitation is that it is centered on colorectal cancer detection rather than broader validation across unrelated lesion types or clinical patient cohorts. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,953 characters · extracted from oa-doi-fallback · click to expand
Abstract Visualization of colorectal cancer (CRC) lesions is complicated by their location in the colon and tumor morphology. Reliance on a single surface biomarker for direct identification risks false negatives due to temporal changes and/or tumor heterogeneity. We developed a multiplexed system of complementary biomarker targets in an effort to capture a broader range of lesions with diverse temporal and/or phenotypic expression. We identified Mucin-1 (MUC1) and epithelial cell adhesion molecule (EPCAM) as useful targeting pairs by examining multiple colon tumor subtypes in a standard tissue array, and by surveying multiple CRC cell lines, both as 2D cultures and as 3D tumoroids, for the presence of the CRC surface biomarkers. We demonstrated the utility of a “universal” surface functionalization approach using Antibody-Protein L functionalized microparticles (APL-MPs) that enabled the simultaneous incorporation of antibodies recognizing MUC1 and EPCAM. Using CRC cell heterogeneous tumoroids expressing both MUC1 and EPCAM (HET-tumoroids) and orthotopic animal cancer models designed to express both surface antigens, we demonstrated that: 1) APL-MPs identified MUC1- and EPCAM-positive tumoroids in proportion to antigen expression; 2) APL-MPs detected CRC surface antigens on the luminal colon surface in vivo, and 3) concurrent targeting of multiple surface antigens enhanced the sensitivity of detection of heterogeneous CRC lesions. This approach opens the door for the use of antibody–protein L dual-targeting MPs in a variety of applications to detect heterogeneous cancer lesions. Significance Multi-antigen targeting of MUC1 and EPCAM with Antibody-Protein L microparticles enhances the detection sensitivity of heterogeneous colorectal cancer lesions, offering a promising strategy for the accurate visualization of tumors in complex environments. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00